| Ytd | -75.16% | |
| 1y | -92.08% |
| Open | 0.41 | Prev Close | 0.42 | Low | 0.41 | High | 0.47 | Mkt Cap | 12.73M |
| Vol | 340.94K | Avg Vol | 539.30K | EPS | -2.58 | P/E | N/A | Forward P/E | -4.89 |
| Beta | 2.20 | Short Ratio | 9.32 | Inst. Own | 100.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.72 | 200-d Avg | 1.45 | 1yr Est | 68.78 |
JSPR News
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001788028/000121390026066782/ea0294010-8k_jasper.ht
Major M&A deals this week include: New Mountail Capital buys Asset Living, SalesForce acquires C
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Per
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the anal
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 wee
Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic ast
MDB: 24% | MongoDB shares are trading higher after the company reported better-than-expected Q3 fina
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Per
JPMorgan downgrades CoreWeave, citing turbulence in AI infrastructure market. Despite near-term chal
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.13) per share which beat the anal
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a
JMP Securities analyst Silvan Tuerkcan maintains Jasper Therapeutics (NASDAQ:JSPR) with a Market
BTIG analyst Justin Zelin maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the p
Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical-stage biotechnology company f
UBS analyst Trung Huynh maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the pri
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.74) per share which missed the an
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runwa
BMO Capital analyst Kostas Biliouris downgrades Jasper Therapeutics (NASDAQ:JSPR) from Outperform
JMP Securities analyst Silvan Tuerkcan maintains Jasper Therapeutics (NASDAQ:JSPR) with a Market
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a
William Blair analyst Matt Phipps downgrades Jasper Therapeutics (NASDAQ:JSPR) from Outperform to
HC Wainwright & Co. analyst Emily Bodnar maintains Jasper Therapeutics (NASDAQ:JSPR) with a B
BTIG analyst Justin Zelin maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the p
Jasper shares drop after updated BEACON study shows strong results but faces disruption from comprom
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is presenting data from the 180mg cohort of the Company'
Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and l
UBS analyst Trung Huynh maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the pri
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.41) per share which missed the an
HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.62) per share which missed the an
UBS analyst Trung Huynh initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating
JMP Securities analyst Silvan Tuerkcan reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Market
HC Wainwright & Co. analyst Emily Bodnar maintains Jasper Therapeutics (NASDAQ:JSPR) with a B
RBC Capital analyst Gregory Renza maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform a